Get the Stockscreener App
25.34
1.40%
-0.36
Pharvaris Nv stock is traded at $25.34, with a volume of 88,517.
It is down -1.40% in the last 24 hours and down -9.34% over the past month.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.
See More
Previous Close:
$25.70
Open:
$25.7
24h Volume:
88,517
Relative Volume:
0.54
Market Cap:
$1.65B
Revenue:
-
Net Income/Loss:
$-180.80M
P/E Ratio:
-7.8757
EPS:
-3.2175
Net Cash Flow:
$-150.76M
1W Performance:
-5.87%
1M Performance:
-9.34%
6M Performance:
+3.77%
1Y Performance:
+63.80%
1-Day Range:
$24.95
$25.70
1-Week Range:
$24.95
$27.13
52-Week Range:
$11.51
$29.80
Pharvaris Nv Stock (PHVS) Company Profile
Compare PHVS vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PHVS
Pharvaris Nv
|
25.34 | 1.65B | 0 | -180.80M | -150.76M | -3.2175 |
VRTX
Vertex Pharmaceuticals Inc
|
448.62 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
741.69 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
677.50 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
308.05 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
275.69 | 30.60B | 5.36B | 287.73M | 924.18M | 2.5229 |
Pharvaris Nv Stock (PHVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-09-26 | Initiated | RBC Capital Mkts | Outperform |
| Oct-15-25 | Initiated | H.C. Wainwright | Buy |
| Oct-09-25 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-11-25 | Initiated | Guggenheim | Buy |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-25-23 | Initiated | Wedbush | Outperform |
| Aug-15-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-05-22 | Initiated | Bryan Garnier | Buy |
| Sep-13-22 | Resumed | JMP Securities | Mkt Outperform |
| Aug-23-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-22-22 | Downgrade | BofA Securities | Neutral → Underperform |
| May-25-22 | Initiated | JMP Securities | Mkt Outperform |
| Mar-02-21 | Initiated | BofA Securities | Neutral |
| Mar-02-21 | Initiated | Morgan Stanley | Overweight |
| Mar-02-21 | Initiated | Oppenheimer | Outperform |
| Mar-02-21 | Initiated | SVB Leerink | Outperform |
View All
Pharvaris Nv Stock (PHVS) Latest News
PHVS.O Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
How Pharvaris N.v. (PHVS) Affects Rotational Strategy Timing - Stock Traders Daily
PHVS.O Technical Analysis & Stock Price Forecast - Intellectia AI
Lancet publishes Phase 2 oral treatment data for rare swelling disorder - Stock Titan
Guggenheim maintains Pharvaris NV (PHVS) buy recommendation - MSN
[Form 3] Pharvaris N.V. Initial Statement of Beneficial Ownership - Stock Titan
Pharvaris (PHVS) director Glassman reports stock options and RSU holdings - Stock Titan
Pharvaris (PHVS) director discloses sizable stock and option holdings - Stock Titan
Pharvaris (NASDAQ: PHVS) director details options, RSUs and shares - Stock Titan
Pharvaris (PHVS) CFO discloses common stock and option holdings - Stock Titan
Pharvaris (NASDAQ: PHVS) CTO reports option grants and share holdings - Stock Titan
Pharvaris (PHVS) CCO reports initial stock, RSU and option holdings - Stock Titan
Pharvaris (PHVS) PAO reports initial share, option and RSU holdings - Stock Titan
Pharvaris (PHVS) director David Meeker reports stock, options and RSUs - Stock Titan
Pharvaris (PHVS) director Viviane Monges details initial equity holdings - Stock Titan
Pharvaris (PHVS) CMO Lu Peng details initial share and stock option holdings - Stock Titan
Pharvaris (PHVS) CEO Berndt Modig details stock, RSUs and options - Stock Titan
Pharvaris (PHVS) CHRO details option and RSU equity holdings - Stock Titan
Is New HAE Patient-Reported Outcome Study Altering The Investment Case For Pharvaris’ Deucrictibant (PHVS)? - simplywall.st
Trend Recap: How sensitive is Pharvaris NV to inflation2026 Risk Factors & Long Hold Capital Preservation Tips - baoquankhu1.vn
Assessing Pharvaris (PHVS) Valuation After New Real‑World HAE Study Supports Deucrictibant Trials - Sahm
Patient attack ratings to guide Pharvaris hereditary angioedema trials - Stock Titan
PHVS: Oral therapies for angioedema show strong data, with launches and key filings expected by 2027 - TradingView
RBC Capital initiates coverage of Pharvaris NV (PHVS) with outperform recommendation - MSN
Pharvaris (NASDAQ:PHVS) Now Covered by Analysts at Royal Bank Of Canada - Defense World
Can Pharvaris (PHVS) Turn Deucrictibant’s Phase 2 Extension Data Into a Durable Franchise Advantage? - simplywall.st
(PHVS) and the Role of Price-Sensitive Allocations - Stock Traders Daily
PHVS Should I Buy - Intellectia AI
Pharvaris N.V. (PHVS) Presents at American Academy of Allergy, Asthma & Immunology (AAAAI) 2026 Annual MeetingSlideshow (NASDAQ:PHVS) 2026-03-05 - Seeking Alpha
Portfolio Recap: Does Pharvaris NV stock have upside surprise potentialQuarterly Portfolio Summary & Scalable Portfolio Growth Methods - baoquankhu1.vn
Movement Recap: How correlated is Pharvaris NV to the S P500July 2025 WrapUp & Weekly Market Pulse Updates - baoquankhu1.vn
Pharvaris N.V. (PHVS) Stock Analysis: Exploring a Promising 65.84% Potential Upside in Biotech - DirectorsTalk Interviews
Responsive Playbooks and the PHVS Inflection - Stock Traders Daily
PHVS: Oral HAE therapy shows strong phase III results, with NDA filing and key data expected this year - TradingView
PHVS Stock Price and Chart — NASDAQ:PHVS - TradingView
Pharvaris N.V. (PHVS) Stock Analysis: A 65% Upside Potential In The Biotech Sector - DirectorsTalk Interviews
Pharvaris shares slide following $175 million equity offering - MSN
A Look At Pharvaris (PHVS) Valuation As Deucrictibant Advances With New Phase 3 And Phase 2 Data - Sahm
Bain Capital Life Sciences shows 4.3% Pharvaris (PHVS) ownership in Schedule 13G/A - Stock Titan
Understanding the Setup: (PHVS) and Scalable Risk - Stock Traders Daily
PHVS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Aug Shorts: What is the Moat Score of Pharvaris N.V.2025 Buyback Activity & Smart Swing Trading Techniques - mfd.ru
Pharvaris N.V. (PHVS) Stock Analysis: Potential Upside Of 75% In The Biotech Sector - DirectorsTalk Interviews
Does Pharvaris N.V. stock have upside surprise potentialIPO Watch & Daily Profit Maximizing Trade Tips - mfd.ru
Will Pharvaris N.V. stock gain from lower inflationEarnings Summary Report & Accurate Trade Setup Notifications - mfd.ru
Will Pharvaris N.V. stock recover faster than peersQuarterly Portfolio Review & Comprehensive Market Scan Insights - mfd.ru
Aug Swings: How sensitive is Pharvaris NV to inflationQuarterly Investment Review & Daily Profit Maximizing Tips - baoquankhu1.vn
Oral drug for hereditary angioedema attacks shows Phase 3 data at AAAAI 2026 - Stock Titan
Aug Outlook: Is Pharvaris NV stock a value trapJuly 2025 Big Picture & High Return Trade Guides - baoquankhu1.vn
Aug Gainers: Can Pharvaris NV stock outperform in a bear marketJuly 2025 Sector Moves & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
Pharvaris Shares Surge After Strong Phase 3 Results for Oral HAE Treatment - MSN
Pharvaris Nv Stock (PHVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.80%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):